Showing 5871-5880 of 7509 results for "".
- Dermavant: First Patient Dosed in Phase 3 Study of Tapinarof in ADhttps://practicaldermatology.com/news/dermavant-first-patient-dosed-in-phase-3-study-of-tapinarof-in-ad/2460925/The first patient has been dosed in the Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD). Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development by
- Nutrafol May Promote Hair Growth in Menopausal Womenhttps://practicaldermatology.com/news/nutrafol-may-promote-hair-growth-in-menopausal-women/2460923/Nutrafol may improve hair growth and quality for perimenopausal, menopausal, and postmenopausal women, according to research presented during The North American Menopause Society (NAMS) Annual Meeting in Washington, DC. Researchers compared results at 6 mont
- Cetaphil Updates Formulas, Launches 16 New Productshttps://practicaldermatology.com/news/cetaphil-updates-formulas-launches-16-new-products/2460922/Cetaphil is updating their formulas and launching 16 new products including their first-ever acne care line. The brand’s most prominent products have been upgraded to feature a blend of Niacinamide (Vitamin B3), Panthenol (Vitamin B5), and hydrating Glycerin to improve skin’
- Cytrellis Secures New Round of Fundinghttps://practicaldermatology.com/news/cytrellis-secures-new-round-of-funding/2460920/Cytrellis has closed a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors, ARCH Venture Partners and PFM Health Sciences. Proceeds will be
- Soligenix to Advance Synthetic Hypericin Development in Psoriasishttps://practicaldermatology.com/news/soligenix-to-advance-synthetic-hypericin-development-in-psoriasis/2460917/Soligenix, Inc. will be expanding synthetic hypericin development under the research name SGX302 into psoriasis. The company made this move after the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated S
- Dr. Eugene A. Bauer Joins American Skin Association Boardhttps://practicaldermatology.com/news/dr-eugene-a-bauer-joins-american-skin-association-board/2460915/Eugene Bauer, MD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Bauer is Professor, Emeritus, at Stanford University School of Medicine. He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermir
- New Publication Supports Diagnostic Value of DermTech's PLAhttps://practicaldermatology.com/news/new-publication-supports-diagnostic-value-of-dermtechs-pla/2460914/Evaluation of genomic atypia with DermTech’s Pigmented Lesion Assay (PLA) increases both the real-world negative predictive value (NPV) and positive predictive value (PPV) of the melanoma diagnostic pathway and reduces biopsy burden, relative to the current visual assessment and histopathol
- World Atopic Eczema Day Focuses on Disease Awarenesshttps://practicaldermatology.com/news/world-atopic-eczema-day-focuses-on-disease-awareness/2460912/As patient communities worldwide join forces to raise awareness about atopic eczema, the International Alliance of Dermatology Patient Organisations (GlobalSkin) and the global atopic eczema community call on healthcare professionals, health policy decision ma
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti